Fea Antonio Maria

Effectiveness of MicroShunt in Patients with Primary Open-Angle and Pseudoexfoliative Glaucoma: A Retrospective European Multicenter Study.

In this retrospective study, the MicroShunt effectively lowered IOP and the need for IOP-lowering medications.

Long-term outcomes after acute primary angle closure of Caucasian chronic angle closure glaucoma patients.

Our study prompts ophthalmologists to closely follow patients after an APAC attack to prevent potential glaucoma damage in both APAC and fellow eye.

The quality of reporting on Glaucoma Surgical Innovations during Early Development Stages using IDEAL Guidelines: a Systematic Review.

Critical aspects of study design and reporting were frequently missing in early-phase surgical studies of glaucoma.

Preserflo MicroShunt in refractory glaucoma: multicentre european results with up to three years of follow-up.

In a real-world, multicentre setting, the Preserflo MicroShunt showed sustained IOP reduction and decreased medication use over 3 years, supporting its long-term safety and efficacy.

Clinical recommendations for early identification of patients with open-angle glaucoma at higher risk of low adherence to topical treatment: An Italian Delphi consensus.

Taken together our results allow us to profile patients with glaucoma who will be more likely to show poor adherence to topical treatments.